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Corporate Social Responsibility, Condition Branding and Ethics in Marketing
Danika V. Hall, Sandra C. Jones, University of Wollongong
Abstract
Over the past two decades there has been increased interest in corporate social responsibility
(CSR) and its relation to marketing practice and theory (Maignan and Ferrell, 2004; Polonsky
and Jevons, 2006). This paper explores another marketing phenomena emerging from the
pharmaceutical industry: condition branding (Angelmar, Angelmar and Kane, 2007; Parry,
2003). Condition branding has been positioned as a form of CSR for the industry, in that it
provides education to the general public regarding diseases or conditions. However, the
ethical nature of condition branding has been questioned as it is also seen as a deliberate
method of increasing markets for pharmaceutical products. This paper raises concerns of
consumers and regulators regarding condition branding and disease advertising, and suggests
how these practices could be better regulated or modified to reflect the principles of CSR.
Introduction
While the term Corporate Social Responsibility (CSR) was coined in the 1950s, the concept
has its roots in social contract theory dating back to 1600s (Langer, 2006). CSR has been
described as an organisation’s social obligation: to pursue policies, make decisions or take
actions that are in line with societal objectives and values (Abratt and Sacks, 1988; Robin and
Reidenbach, 1987). More recently, CSR has been considered in relation to the groups or
stakeholders that are directly or indirectly affected by the activities of the organisation, such
as employees, customers, shareholders, suppliers and the local community (Langer, 2006;
Maignan and Ferrell, 2004). The benefits of CSR for an organisation can include increased
customer loyalty, employee commitment, supplier support and improved corporate reputation
(Maignan, Ferrell and Ferrell, 2005). CSR can be seen as part of a greater change in corporate
philosophy and practice over the past two decades: the business ethics movement (Weber,
2006). Weber (2006) refers to the mantra “good ethics is good business” which implies that
“following high ethical standards is related to – and contributes to – business success” (p.15).
Within this movement it is recognised that ethical and socially responsible behaviour can give
organisations a competitive advantage, whereas behaviour that creates suspicion or is
seemingly contradictory to the organisation’s purpose can reduce the chance of business
success (Abratt and Sacks, 1988).
Over the past decade, disease awareness advertisements sponsored by pharmaceutical
companies have become increasingly prevalent (Mintzes, 2006a). In the US and Canada, these
are commonly referred to as ‘help seeking advertisements’ (Food and Drug Administration,
2004; Mintzes, 2006b), whereas in the UK they are referred to as ‘disease awareness
campaigns’ (Carpenter, 2003). These advertisements or campaigns usually focus on a disease
or condition and provide information on symptoms or a range of treatments without
mentioning a specific product or brand. They usually refer consumers to websites or other
information sources, or encourage them to speak with their doctor. For example, a Pfizer
advertisement regarding Alzheimer’s disease has appeared in Reader’s Digest Magazine in
Australia, with a list of potential symptoms and the statement “If you recognise any of these
signs or symptoms, check with your doctor” (Pfizer Australasia Pty Ltd, 2004). Disease
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awareness advertisements such as these can be considered as a component of a new and
broader marketing strategy within the pharmaceutical industry: ‘condition branding’.
In a recent article, Angelmar, Angelmar and Kane (2007) propose that the pharmaceutical
marketing paradigm be broadened to include the building of strong condition brands. They
define condition branding as “the deliberate management of patient, physician, payer and
other stakeholder knowledge about a condition in order to improve how the condition is
treated” (p342). This definition suggests that all stakeholders are considered important
audiences in condition branding and that the over-riding motivation is improving treatment. It
also suggests that condition branding is a form of socially responsible behaviour for the
pharmaceutical industry. In a discussion regarding why companies should invest in condition
branding, the authors state that, aside from increasing sales and raising the total number of
prescriptions, it could be “for ethical reasons, or because they see image benefits” (Angelmar
et al., 2007 p. 348). The idea of pharmaceutical marketing practices as a function of
improving corporate credibility or reputation has previously been suggested with regard to
disease awareness advertising as well as direct-to-consumer advertising (DTCA) for
prescription medicines (see for example Bonaccorso and Sturchio, 2002; Carpenter, 2003;
Wielondek, 2005). However Parry (2003) positions condition branding more purely as a
profit-motivated function. He suggests that “if you can define a particular condition and its
associated symptoms in the minds of physicians and patients, you can also predicate the best
treatment for that condition” (p.43). Parry (2003) identifies three strategies in condition
branding: increasing the importance of a disease; re-defining or reducing stigma relating to a
disease; or developing a new condition to create recognition of an unmet need, then
introducing the product to meet that need.
Based on these descriptions in the marketing literature, it can be considered that the
motivation for condition branding and producing disease awareness campaigns for
pharmaceutical companies is three-fold:
1. Increasing the market: create a sense of need for a product (category need) by
generating greater knowledge, acceptance or significance of a condition/disease
2. Increasing product awareness: create greater association between the company’s
pharmaceutical product and the condition it is designed to treat in the minds of
prescribing doctors as well as consumers (with a view to increasing prescriptions)
3. Increasing corporate credibility: position the manufacturer as a socially responsible,
trustworthy organisation contributing to the education of consumers and other
stakeholders in an effort to improve early diagnosis and/or treatment of
conditions/diseases.
One of the few published empirical studies of disease awareness campaigns was documented
by t’Jong, Stricker and Sturkenboom (2004) and reports on a campaign sponsored by
pharmaceutical company Novartis in the Netherlands that created awareness and heightened
the importance of a relatively benign foot fungal condition known as onychomycosis. The
study found that as a result of the campaign prescription rates for terbinafine (a product made
by Novartis to treat onychomycosis) and onychomycosis-related consultations increased,
while prescriptions for the competitor product decreased. t’Jong et al (2004) were critical of
the impact of the campaign on the workload of doctors and state that the Dutch Society of
General Practitioners (GPs) opposed the campaign as “an unnecessary focus on an
unimportant health problem” (p. 931). As such, this condition branding by Novartis achieved
increased awareness of a product, as well as increased prescriptions, however it failed to
increase corporate credibility. As a result of the campaign, some GPs in the Netherlands
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called for a ban on Novartis products (Sheldon, 2002). Novartis has also been criticised in
Australia (Hall and Jones, 2007a), the US (Langreth and Herper, 2006), and the UK (Jackson,
2003) for similar campaigns. This leads us to consider whether condition branding, and
disease awareness advertising, should be considered as a form of CSR.
Stakeholder concerns
Recent perspectives of CSR consider that the corporation is obligated to consider the groups
or actors that are directly or indirectly affected by the activities of that corporation, such as
employees, customers, shareholders, suppliers and the local community (Langer, 2006;
Maignan and Ferrell, 2004). As part of this approach, organisations adopt a perspective in
their strategic planning and operational processes which serves to maximise positive impacts
and minimise negative impacts on stakeholders. In the pharmaceutical industry, stakeholders
include stockholders, suppliers, contractors, employees, patients, doctors, other healthcare
professionals, medical journal editors, clinical researchers, medical educators, healthcare
payers, healthcare policy makers, and people who need but do not have access to
pharmaceutical products (Weber, 2006). The following section, however, will only consider
the practices of condition branding and disease awareness advertising in relation to two
stakeholder groups: consumers (including consumer organisations and public health
advocates) and regulators (government or industry bodies).
Consumers
In reviewing literature regarding condition branding and disease awareness campaigns, it
appears that consumers are concerned that such campaigns will only focus on diseases where
there are large and lucrative markets, for example lifestyle conditions such as obesity and
hair-loss (Consumers International, 2006; Glatter, 2004). This has been the case for the
practice of DTCA, as content analyses of US magazines have found the most advertised
products were for chronic, non-life-threatening diseases or lifestyle choices (Holmes and
Desselle, 2004; Roth, 1996). A recent Australian survey found that consumers most
commonly recalled seeing advertisements in the mass media for erectile dysfunction and
weight loss (Hall and Jones, 2007b). There is further concern that these practices can
exaggerate the risk or prevalence of a condition (Mintzes, 1998; Mintzes, 2006a) and that this
may result in increased community fear and anxiety and unnecessary visits to doctors. A
recent example is an Australian disease awareness campaign for genital herpes which stated
that “one in 8 of us … have genital herpes”, however the image was six female symbols, two
of which were highlighted red, visually suggesting that one third of Australian women have
genital herpes (GlaxoSmithKline, 2006).
Additionally, there is concern when condition branding and disease awareness advertising
utilises persuasive techniques to encourage consumers to identify with symptoms such that
they may begin to consider normal events (such as mood fluctuations or daily frustrations) as
part of a serious health problem (such as a psychiatric disorder) which requires medical
treatment (Moynihan and Cassels, 2005). Examples include the advertising of Pre-menstrual
Dysphoric Disorder (an extreme form of Pre-menstrual tension) in the US, and the promotion
of Social Anxiety Disorder or Social Phobia (an extreme form of shyness) in the US and
Australia (Moynihan and Cassels, 2005). An artist recently received some recognition for a
parody on pharmaceutical companies medicalising normal life experience (often referred to as
‘disease mongering’). Her campaign for a ‘new’ disorder known as Dysphoric Social
Attention Consumption Deficit Anxiety Disorder with symptoms including stress and weight-
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gain, coincided with the launch of a ‘new’ pharmaceutical product, Havidol, and was
complete with faux television and print advertisements as well as a website (Burke, 2007).
Regulators
In countries where DTCA of prescription medicines is not allowed - including Australia,
Canada, the European Union and the UK - pharmaceutical companies are prohibited from
advertising prescription products directly, but can sponsor disease awareness advertisements.
These advertisements often fall under the regulation of pharmaceutical industry bodies (self
regulation). Such is the case in Australia, where Medicines Australia’s voluntary Code of
Conduct prohibits advertising branded prescription medicines (in keeping with the
Therapeutic Goods Act 1989) but allows for ‘patient education’ (Medicines Australia, 2006).
Patient education is described as educational information on medical conditions and the range
of treatments that may be prescribed by a doctor (Medicines Australia, 2006).
Of concern for regulators is when pharmaceutical companies use disease awareness
campaigns to directly promote their products to consumers under the guise of education, and
evade the ban on DTCA (Gardner, Mintzes and Ostry, 2003; Mintzes, 2006a). There is
increasing evidence of pharmaceutical companies using branding techniques (such as special
fonts, colours, logos, campaign names and spokes-characters) to create pseudo brands without
actually naming the product, and via advertising they create an association between their
product and a condition/disease (Hall and Jones, 2007a), for example recent advertisements
featuring a tiger character that is synonymous with Viagra. In some instances, these
advertisements provide limited disease information but encourage patients to ask their doctor
about new available treatments. There is also evidence that disease advertising directed at
consumers occurs concurrently with branded campaigns targeting doctors so that doctors can
recall (and potentially prescribe) the product when patients discuss the disease advertisement
with them (Glatter, 2004; Mackenzie et al., 2007).
Some of these issues, and the consumer concerns described above, have been considered by
the Australian Government in a National Competition Review of Drugs, Poisons and
Controlled Substances Legislation (Galbally, 2000). The concern that some disease awareness
advertisements convey limited educational information, and use branding techniques to
convey a product identity, have also been noted by the Medicines Australia Complaints
Committee - see deliberations of complaints 676 and 767 in Code of Conduct Annual
Reports (Medicines Australia, 2003; Medicines Australia, 2005). Medicines Australia have
the opportunity to redress some of these concerns by stipulating more specific and detailed
guidelines regarding what constitutes disease awareness advertising or patient education.
Other countries, including the UK’s Medicines and Healthcare Products Regulatory Agency
and the Pharmaceutical Research and Manufacturers Association in the US, have developed
detailed guidelines relating to this form of advertising (MHRA, 2003; PhRMA, 2005).
Corporate social responsibility and ethical marketing
Within the pharmaceutical industry there is belief that condition branding and disease
awareness advertising is a form of CSR, because it provides consumer education that may
lead to early diagnosis and treatment, with potential for other public health benefits
(Angelmar et al., 2007; Wielondek, 2005). It has been argued that because ill health is one of
the most tangible forms of suffering, the pharmaceutical industry often believes it can link its
marketing activities to ethical objectives (Applbaum, 2006). However, Parsons (2007) has
examined condition branding as a communication strategy against the ‘Five Pillars of Public
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Relations Ethics’: the objective to do no harm; the objective to do good; telling the truth;
maintaining privacy; and fairness and social responsibility. She found that condition branding
failed against each of the pillars, with the exception of maintaining privacy, and concluded
that disease branding is an unethical marketing communication strategy (Parsons, 2007).
In a review of pharmaceutical marketing in Europe, Consumers International (2006) describe
that disease awareness advertising is often disguised as CSR, because it creates consumer
demand for drugs for pharmaceutical products, while giving consumers a sense of trust in the
advertisers. Polonsky and Jevons (2006) state that CSR should reflect the core value of
activities and strategic direction of corporations, and that it should not be an illusive method
to improve corporate image or achieve differentiation. Robin and Reidenbach (1987) discuss
the concept of CSR being congruent with marketing objectives – as would be anticipated by
consumers. They argue that “all of the parts must fit together to produce a logical, internally
consistent and easily communicated ethical profile” (page 54). Pharmaceutical companies
engaging in condition branding, and framing it as a form of CSR, run the risk of creating
considerable consumer skepticism and, as a consequence, reduced corporate credibility.
However, companies also have the opportunity to be upfront regarding the purpose of their
advertising, such as including some form of generic disclosure that the advertisers make
product(s) to treat or prevent the condition advertised.
If industry sponsored disease awareness advertisements were to be considered as a form of
CSR, it would be important that the sponsors provide balanced and accurate information
regarding important diseases other than those that they produce a treatment for. Wielondek
(2005) provides an overview of the declining corporate image of the pharmaceutical industry
and the negative impacts of product recalls and DTCA in the US. She suggests that disease
awareness campaigns provide an opportunity for the pharmaceutical industry to regain
corporate credibility if they are carefully planned and implemented to minimise negative
effects. She proposes the opportunity for a disease awareness advertising campaign
promoting, for example, diabetes lifestyle improvement programs, in an effort to regain
corporate credibility (Wielondek, 2005). There are many other CSR opportunities for
pharmaceutical companies, including those unrelated to advertising or provision of disease
information. Ross-Wooldridge et al (2004) describe that pharmaceutical companies can
become more competitive and develop greater brand equity via socially responsible actions
such as providing essential pharmaceutical products to the least developed nations at low cost.
Conclusion
Condition branding and disease awareness advertising are marketing practices increasingly
being used by the pharmaceutical industry, however they have the potential to negatively
impact upon stakeholders. They could increase consumer fear and anxiety, and unnecessary
visits to doctors, and regulators may be concerned with how these practices skirt current
guidelines for the advertising of prescription medicines. While these practices have been
positioned as a form of CSR within the industry, it is clear that they are at odds with what
traditionally constitutes CSR. Disease awareness advertising that might constitute CSR is
where the advertiser does not serve to benefit, such as a non-pharmacological behaviour
change or prevention campaign. Further research is needed to explore the extent and nature
of, as well as consumer attitudes towards, condition branding and disease awareness
advertising in order to determine impacts on stakeholders and to inform future regulation.
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